ストックスクリーナーアプリを入手
7.50
4.34%
-0.34
アフターアワーズ：
7.59
0.09
+1.20%
前日終値:
$7.84
開ける：
$7.71
24時間の取引高:
57,579
Relative Volume:
0.37
時価総額：
$44.64M
収益：
$7.97M
当期純損益:
$-75.74M
株価収益率:
-0.3088
EPS:
-24.2853
ネットキャッシュフロー:
$-85.33M
1週間 パフォーマンス:
+4.02%
1か月 パフォーマンス:
+4.17%
6か月 パフォーマンス:
-81.67%
1年 パフォーマンス:
-25.76%
1日の値動き範囲:
$7.30
$7.74
1週間の範囲:
$6.8242
$8.06
52週間の値動き範囲:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
名前
Aligos Therapeutics Inc
セクター
電話
(800) 466-6059
住所
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
ALGS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
7.50 | 44.64M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-19 | 開始されました | H.C. Wainwright | Buy |
| 2023-01-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-01-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-09 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 再開されました | Piper Sandler | Overweight |
| 2020-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 開始されました | JP Morgan | Overweight |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Aligos Therapeutics Inc (ALGS) 最新ニュース
Aligos Therapeutics (ALGS) Welcomes New VP of Chemistry Manufacturing Controls | ALGS Stock News - GuruFocus
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing - Bluefield Daily Telegraph
Aligos Therapeutics Strengthens Drug Development Team: Former Kezar Executive to Drive Phase 2 Trial Progress - Stock Titan
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Aligos Therapeutics (ALGS) Issues Stock Options to New Employees | ALGS Stock News - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics Awards Major Stock Options Package: New Employees Get 26,000 Shares Under Nasdaq Rule - Stock Titan
(ALGS) Long Term Investment Analysis - news.stocktradersdaily.com
5,157 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Bought by Northern Trust Corp - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Decline in Short Interest - Defense World
Clinical Stage Liver Disease Biotech Aligos Set for Major Jefferies Conference Presentation - Stock Titan
How the (ALGS) price action is used to our Advantage - news.stocktradersdaily.com
Financial Comparison: Entera Bio (NASDAQ:ENTX) versus Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (ALGS) Appoints New Head of Legal | ALGS Stock News - GuruFocus
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal - The Manila Times
Former Genentech and Codexis Legal Leader Takes Top Legal Role at Liver Disease Biotech Aligos - Stock Titan
Aligos Therapeutics Issues 26,000-Share Inducement Grant To New Employee - Nasdaq
Aligos Therapeutics (ALGS) Awards New Employee Stock Option Gran - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ALGS Stock News - GuruFocus
Aligos Therapeutics (ALGS) Awards New Employee Stock Option Grant | ALGS Stock News - GuruFocus
Aligos Therapeutics Expands Liver Disease Team with Strategic Hire, Awards 26,000 Share Options - Stock Titan
Aligos Therapeutics First Quarter 2025 Earnings: Revenues Miss Expectations - Yahoo Finance
Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation - simplywall.st
Aligos reports promising HBV treatment data at EASL Congress - Investing.com
Aligos Therapeutics (ALGS) Showcases Promising HBV Treatment Results at EASL Congress 2025 | ALGS Stock News - GuruFocus
Aligos reports promising HBV treatment data at EASL Congress By Investing.com - Investing.com Nigeria
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 - The Manila Times
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates - MSN
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results - ADVFN
Aligos Therapeutics Reports Strong Q1 2025 Progress - TipRanks
Aligos Therapeutics (ALGS) Reports Lower Q1 Revenue, Advances Ke - GuruFocus
Aligos Therapeutics Inc Reports Q1 2025 EPS of $5.12, Surpassing Estimates; Revenue Slightly Misses at $0.31 Million - GuruFocus
ALIGOS THERAPEUTICS Earnings Results: $ALGS Reports Quarterly Earnings - Nasdaq
Aligos Therapeutics, Inc. SEC 10-Q Report - TradingView
Aligos Reports Surprise $43M Profit: Breakthrough HBV Drug Shows 100% Response Rate at 96 Weeks - Stock Titan
Aligos Therapeutics secures $105 million in private placement - MSN
Aligos Therapeutics (ALGS) Projected to Post Earnings on Tuesday - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stake Lessened by Renaissance Technologies LLC - Defense World
Aligos Therapeutics Inc expected to post a loss of $2.80 a shareEarnings Preview - TradingView
Aligos Therapeutics (ALGS) Gains Buy Rating with Promising Outlo - GuruFocus
Aligos Therapeutics (ALGS) Coverage Initiated with Positive Outl - GuruFocus
Wells Fargo & Company MN Invests $869,000 in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Geode Capital Management LLC Buys 3,197 Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025 - The Manila Times
Aligos Therapeutics Q1 2025 Earnings: Clinical Stage Biotech Reports Pre-Market May 6Key Focus Areas - Stock Titan
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 - The Manila Times
When the Price of (ALGS) Talks, People Listen - news.stocktradersdaily.com
ALGS stock touches 52-week low at $4.21 amid market challenges By Investing.com - Investing.com South Africa
ALGS stock touches 52-week low at $4.21 amid market challenges - Investing.com India
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% - MSN
Aligos Therapeutics Inc (ALGS) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
2.14%
大文字化:
|
ボリューム (24 時間):